Source: Web Search Revision Year: 2021 Publisher: Manufactured by: Taisho Pharmaceutical Co., Ltd. Omiya Factory 403, Yoshino-cho 1-chome, Kita-ku, Saitama-shi, Saitama, Japan
Lusefi is indicated in the treatment of type 2 diabetes mellitus to improve glycemic control in adults as:
Monotherapy
When diet and exercise alone do not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate due to intolerance.
Add-on combination therapy
In combination with glucose-lowering medicinal products including insulin preparations in adult patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise plus monotherapy does not provide adequate glycemic control. (For study results with respect to combinations and effects on glycemic control see “CLINICAL STUDIES, 2. Add-on combination therapy”)
Usually for adults, 2.5 mg as luseogliflozin should be orally administered once daily before or after breakfast. When the effect is insufficient, the dose can be increased to 5 mg once daily while closely monitoring the clinical course.
The efficacy of luseogliflozin is dependent on renal function, and efficacy is reduced in patients who have moderate renal impairment and likely absent in patients with severe renal impairment. Lusefi is not recommended for use in patients with moderate to severe renal impairment (patients with creatinine clearance [CrCl] <60 ml/min or estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m²).
No dosage adjustment is necessary for patients with mild or moderate hepatic impairment.
(1) Because physiological function is generally impaired in elderly patients, Lusefi should be administered carefully while monitoring the conditions of patients.
(2) Because detection of the symptoms of dehydration (including thirst) may be delayed in elderly patients, caution should be exercised.
The safety and efficacy of luseogliflozin in children aged 0 to <20 years have not yet been established. No data are available.
Single doses up to 25 mg (5 times the maximum recommended human dose) of luseogliflozin in healthy subjects was generally well-tolerated.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status. The removal of luseogliflozin by haemodialysis has not been studied.
Store below 30℃.
Lusefi 2.5 mg film-coated tablets: PTP 100 tablets.
Lusefi 5 mg film-coated tablets: PTP 100 tablets.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
